The global blood screening market size is predicted to worth USD 3.55 billion by 2026 from valuing USD 2.27 billion in 2021, growing at a CAGR of 9.3% during the forecast period. The market is exhibiting obvious potential in the specified gauging period. The market keeps on picking up the energy with the quick increment in the reception of these devices among patients and dispatch of mechanically propelled, easy-to-understand devices into the market.
Blood screening refers to a variety of tests performed on blood samples to diagnose illnesses including AIDS, hepatitis, and syphilis, as well as other clinical situations, including pregnancy. It aids in detecting and preventing diseases and a range of other conditions such as infections and cancer. Before donating blood, blood donors are subjected to screening to prevent the transmission of infection. Blood is a liquid-based biological substance that has multiple cells and proteins floating in it. It is a fluid that contains red blood cells, white blood cells, and platelets and circulates throughout the body. Through capillaries, arteries, and veins, it transports oxygen and nutrients to the body's cells. It also aids the body's removal of metabolic waste and carbon dioxide. Blood screening aids in detecting and preventing illnesses and a range of other diseases such as infections and cancer.
The nucleic acid amplification test was initially introduced in six European countries, France, Germany, Italy, Spain, the UK, and Switzerland, in early 1999 and 2001.
Y-O-Y in the growth in the number of blood donations, the prevalence of newer pathogens, and the increased incidence of contagious diseases are primarily accelerating the growth rate of the global blood screening market.
Increasing blood donations among people is one of the significant factors propelling the global blood screening market during the forecast period. Blood donation among the people has increased from 3.4% in 2008 to 3.6% in 2010. Nearly 2million people donate blood regularly in Germany every year. Additionally, factors such as a high patient pool and increasing disposable income of the people across the regions are likely to propel the market. Advancing healthcare infrastructure, raising awareness regarding maintaining blood safety, and rising healthcare expenditure are expected to drive the blood screening market during the forecast period. Acquisitions and mergers and critical developments, and supply chain trends are driving the market. Moreover, initiatives, investment, and funding the government to create awareness among the people about the safety blood donation influence market growth. In addition, technological advancements in blood screening methods drive market growth. Over the forecast period, rising technical developments and introducing new technologies such as pathogen reduction technology, microbiological screening, and multiplexing are likely to provide significant revenue possibilities for companies in the target market. The most common blood-screening tests include screening donated blood in blood banks for transfusion-transmitted pathogens and blood testing for infectious illnesses in hospitals and clinical laboratories, which positively impacts the market revenue.
Furthermore, emerging countries worldwide provide lucrative growth opportunities for market players operating the market, thereby increasing market growth. growing blood campaigns across the developing countries and increasing voluntary blood donors uplift the market growth. Growing need to diagnose samples and increasing infectious diseases is elevating the demand of the market. The government has taken so many initiatives to bring awareness among the people related to donating blood and screening before transfusion, which accelerates the blood screening market growth.
The global blood screening market is expected to grow rapidly shortly and to provide lucrative growth opportunities such as the emergence of microbiology screening, multiplexing, and pathogen reduction technologies. Also, factors like the increasing economies of developing nations and technological improvements are expected to offer another set of opportunities for the market's growth.
The primary factor restraining the blood screening market is the high cost, which needed to be reduced. Lack of awareness among the people about donating blood may also hamper market growth. Lack of lab technicians among the hospitals and clinical laboratories may also restrict the market growth over the review period. Strict regulations to approve new screening devices into the market over the analysis period may limit the growth. The availability of other alternative technologies like digital immunoassays restricts the blood screening market growth over the period.
Impact of covid-19 on the global blood screening market:
However, due to the pandemic's lockdown and limitations, the number of blood donors and blood transfusion-related tests has decreased. Due to the lockdowns and the fear of becoming infected, the number of blood donations decreased dramatically, as did the number of blood transfusion-related tests. The emergence of COVID-19 has influenced the blood screening market both positively and negatively during the pandemic period. Owing to the disease outbreak, major companies worldwide have been performing several serological tests to detect novel coronavirus antibodies. For instance, the United States Food and Drug Administration (FDA) has given Emergency Use Authorization (EUA) to around 50 serological tests that detect COVID-19 antibodies. These tests are used to determine the virus's seroprevalence in a specific population. Furthermore, there has been a significant increase in hospitalizations, which is projected to boost demand for donated blood or its components and positively impact the blood supply. However, after the lockdown limitations were lifted, the amount of blood donors has soared. The American Red Cross has also begun testing all blood, platelets, and plasma donations for COVID-19 antibodies to inform donors about their exposure to the coronavirus. Thus, the overall impact of COVID-19 is expected to contribute positively toward the growth of the blood screening market.
Market Size Available
2020 to 2026
2021 to 2026
By Technology, Product, End User, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global blood screening market has been segmented and sub-segmented based on the technology, product, end-user, and region.
Blood Screening Market - By Technology:
Based on technology, the nucleic acid amplification segment is expected to dominate the global blood screening market due to factors such as the increasing applications of NAT technology and the growing number of blood donations.
The Elisa segment is expected to occupy the second-largest share in the global blood screening market over the period due to the low cost and standard increase of infectious diseases.
Blood Screening Market - By Product:
Based on the product, the reagents & kits segment is accounted for the largest share and maintains its dominance over the period. Cost-effectiveness and specificity in examining the appearance of various elements drive this market segment to the extent.
The instruments segment accounts for the highest share in the market due to the introduction of new devices into the market by key players.
Blood Screening Market - By End User:
Based on end-user, the blood bank segment is contributing a significant share of the revenue. Moreover, it is likely to grow further during the forecast period due to factors like increasing organ transplantation surgeries, increasing awareness about blood donation and safety, and increasing investments from private and public organizations.
Blood Screening Market – By Region:
Regionally, North America accounted for the majority of the global market share in 2019 due to the existence of many key players and the acquisition of blood screening procedures. In this region, the US is expected to lead the blood screening market due to advanced technologies in using these for screening.
Europe occupies the second-largest share in the blood screening market over the analysis period due to factors like the growing number of steps taken by the government and other organizations in blood donations, screening & transfusion activities over different countries. Germany is projected to hold the largest share in the blood screening market. It is estimated to maintain its position over the period due to growth in awareness about blood donation in the country of this region.
At the same time, Asia-Pacific is expected to have a quick and fast growth rate in the blood screening market over the analysis period. The market growth owes to the growing number of blood donations, a moderate increase of new pathogens, and a great appearance of high-quality infrastructure towards clinical and hospital laboratories in the blood screening market during the period. China, Japan, and India are significant contributors to the blood screening market due to the increasing concentration of key players in existing countries.
The blood screening market of the Latin America region is considered to have stable and steady growth over the period, which owes to government initiatives in bringing awareness among the people. Growing awareness about the safety of the blood bolsters market growth of this region. Mexico is leading the market and continues its dominance over the period, followed by Brazil and Argentina.
The blood screening market of the Middle East & Africa region is projected to have a slow and least share due to the growing number of blood donations. Also, factors like cost, strict government regulations for the product approval of new screening devices may hamper the blood screening market growth during the forecast period. Therefore, UAE, Africa, GCC, KSA, and other countries majorly contribute to the market.
KEY MARKET PLAYERS:
The most promising companies dominating the Global Screening Market profiled in this report are Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics, Danaher Corporation, Abbott Laboratories, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Grifols, Siemens AG, and Beckman Coulter, Inc.
RECENT MARKET DEVELOPMENTS
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.1 Nucliec Acid Amplification Test
6.3.1 Transcription-Mediated Amplification (TMA)
6.3.2 Real-Time Polymerase Chain Reaction (PCR
220.127.116.11 ELISA Market, By Platform
18.104.22.168.1 Chemiluminescence Immunoassay (CLIA)
22.214.171.124.2 Fluorescence Immunoassay (FIA)
126.96.36.199.3 Colorimetric Immunoassay (CI)
188.8.131.52 ELISA Market, By Generation
184.108.40.206.1 First-Generation ELISA
220.127.116.11.2 Second-Generation ELISA
18.104.22.168.3 Third-Generation ELISA
22.214.171.124.4 Fourth-Generation & Above
5.1.5 Flourescence Assay
5.1.6 Rapid Test
5.1.8 Western Blotting
5.1.9 Y-o-Y Growth Analysis, By Technology
5.1.10 Market Attractiveness Analysis, By Technology
5.1.11 Market Share Analysis, By Technology
126.96.36.199 Rental Purchase
188.8.131.52 Outright Purchase
5.2.2 Reagent and Kits
184.108.40.206 NAT Reagents & Kits
220.127.116.11.1 Enzymes and Polymerases
18.104.22.168.2 Standards and Controls
22.214.171.124.3 Probes and Primers
126.96.36.199.4 Buffers, Nucleotides and Solutions
188.8.131.52.5 Labeling and Detection Reagents
184.108.40.206 ELISA Reagents & Kits
220.127.116.11.3 Conjugates (Antigen Or Antibody-Conjugated Enzyme)
18.104.22.168.4 Substrates (Of Enzymes)
22.214.171.124.5 Sample Diluents and Wash Solutions
5.2.4 Y-o-Y Growth Analysis, By Product
5.2.5 Market Attractiveness Analysis, By Product
5.2.6 Market Share Analysis, By Product
5.3 End User
5.3.1 Blood Bank
5.3.3 Y-o-Y Growth Analysis, By End User
5.3.4 Market Attractiveness Analysis, By End User
5.3.5 Market Share Analysis, By End User
5.3.9 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Technology
184.108.40.206 By Product
220.127.116.11 By End User
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Technology
126.96.36.199 By Product
188.8.131.52 By End User
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Technology
18.104.22.168 By Product
22.214.171.124 By End User
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific
8.3 Roche Diagnostics
8.5 Bio-Rad Laboratories
8.6 Siemens Heathineers
8.7 Abbott Laboratories
8.8 Ortho Clinical diagnostics
8.10 Dickinson and Company
8.11 Beckman Coulter
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables